Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 14/20 | 0.41 |
| ▸ | MAP3K8 | P41279 | 9/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799418 | 0.68 | ALDH1A1 (0.42) | STK17BMAP3K8STK17A | |
| SCHEMBL4420334 | 0.66 | STK17B (0.40) | STK17BMAP3K8STK17A | |
| SCHEMBL6221005 | 0.65 | STK17B (0.53) | STK17BMAP3K8STK17A | |
| SCHEMBL4431418 | 0.63 | STK17B (0.43) | STK17BMAP3K8STK17A | |
| SCHEMBL6221009 | 0.61 | STK17B (0.48) | STK17BMAP3K8STK17A | |
| SCHEMBL4801988 | 0.57 | SMN1; SMN2 (0.48) | STK17BMAP3K8STK17A | |
| SCHEMBL19997060 | 0.56 | IKBKB (0.61) | STK17BMAP3K8STK17A | |
| SCHEMBL6836416 | 0.55 | EGFR (0.46) | — | |
| SCHEMBL13948944 | 0.54 | EGFR (0.47) | — | |
| SCHEMBL24253524 | 0.54 | EGFR (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | STK17B 3376/4885MAP3K8 1634/4885STK17A 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.